Galmed Pharma (GLMD) Commences Dosing in Aramchol Phase 2a
Galmed Pharma (NASDAQ: GLMD) the first administration of its drug candidate, aramchol, in its proof-of-concept Phase IIa clinical trial for ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)